Wednesday, 17 January 2018

Pacific Edge Limited

NZX : PEB

0.3500
16 Jan 18 17:00
Change:
 0.01
Open:
0.3600
High:
0.3600
Ask:
0.3600
Volume:
470,588
Change(%):
2.78
Prev:
0.3600
Low:
0.3500
Bid:
0.3500
Avg vol:
0
Profile
Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer.
Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). The bladder cancer technology Cxbladder® has been released to the market in Australia and New Zealand. CRC is being readied for commercial release. Pipeline products still in development include gastric and endometrial cancers and melanoma.
Cxbladder® is a non-invasive, accurate test that enables the early detection of bladder cancer from a small volume of urine providing general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy.
The Company is commercialising its products from its new diagnostic laboratory in New Zealand and plans further commercialisation in the US and Europe as a centralised diagnostic service through its own facilities or as a turn-key solution, licensed to selected partners. Pacific Edge has plans for further studies in key markets to engage leading medical and urological opinion leaders who will be vital to success in new markets.
Summary
Shares:399,704,400
Issuer:Pacific Edge Limited
Solicitor:Anderson Lloyd Caudwell Dunedin
Registry:LINK MARKET SERVICES LIMITED
Auditor:Pricewaterhouse Coopers Dunedin
Settlement:NZCDC Settlement System
Website:http://www.peblnz.com/
Fundamentals
Market Cap:$139,896,540
52 wk High:0.6000
52 wk Low:0.3100
Sector:Investment
NTA:0.0260
Address
Pacific Edge Limited
87 St David Street
Dunedin 9016
New Zealand
Latest News
Announcements
  • PACIFIC EDGE LIMITED INTERIM REPORT 2017

    14:51 | 19/12/17
    NZX
    Attached please see your Interim Report 2017 for the six months to 30 September 2017. End CA:00312170 For:PEB Type:INTERIM Time:2017-12-19 14:51:10 more»
  • Interim Results - Half Year End 30 September 2017

    09:26 | 29/11/17
    NZX
    Pacific Edge FY18 Interim Results Results for the six months to 30 September 2017 Performance Snapshot o 41% increase in Operating Revenue to $4.2m, compared to pcp o Lab more»
  • PEB Price Enquiry

    16:54 | 27/11/17
    NZX
    28 November 2017 Logan Thompson NZX Regulation NZX Limited PO Box 2959 Wellington 6140 By email: surveillance@nzx.com regulation@nzx.com Dear Logan PEB Price Enqui more»
  • PE Half Year Results to be Announced 29 November 2017

    10:21 | 20/11/17
    NZX
    20 November 2017 Pacific Edge Half Year Results to be Announced 29 November 2017 Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), advises the release of its inter more»
  • SPH Notice - First NZ Capital Group Limited

    13:02 | 17/11/17
    NZX
    Disclosure of movement of 1% or more in substantial holding or change in nature of relevant interest, or both Sections 277 and 278, Financial Markets Conduct Act 2013 To NZX more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
Add a Comment
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW
Global Indices
CodeLastChange
NZ508,251390.48%
COMP7,261490.68%
DJI25,8032280.89%
SP5002,786190.67%
DAX13,4662361.78%
FTSE7,48850.07%
NI22522,4204081.86%
TWI73.950.150.21%
Currencies
CodeLastChange
EURUSD1.2210.0070.55%
NZDUSD0.72610.00360.49%
AUDUSD0.79370.00290.36%
NZDAUD0.91490.00110.12%